These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 24457342)

  • 21. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Demographic and clinical factors correlated with clinical outcomes among people with HIV treated by antiretroviral therapy: a retrospective cohort study.
    Li Y; Liu H; Zhang S; Zhang Y; Wang H; Zhang H; Li X
    BMC Infect Dis; 2024 May; 24(1):514. PubMed ID: 38778273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis.
    Ravimohan S; Tamuhla N; Steenhoff AP; Letlhogile R; Makutu DK; Nfanyana K; Rantleru T; Tierney A; Nkakana K; Schwartz AB; Gross R; Macgregor RR; Bellamy SL; Frank I; Weissman D; Bisson GP
    J Infect Dis; 2013 Dec; 208(11):1784-93. PubMed ID: 23908475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).
    Trickey A; May MT; Schommers P; Tate J; Ingle SM; Guest JL; Gill MJ; Zangerle R; Saag M; Reiss P; Monforte AD; Johnson M; Lima VD; Sterling TR; Cavassini M; Wittkop L; Costagliola D; Sterne JAC;
    Clin Infect Dis; 2017 Sep; 65(6):959-966. PubMed ID: 28903507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study.
    Franke MF; Robins JM; Mugabo J; Kaigamba F; Cain LE; Fleming JG; Murray MB
    PLoS Med; 2011 May; 8(5):e1001029. PubMed ID: 21559327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of CD4 count measurement in the era of universal antiretroviral therapy: an analysis of routine laboratory data in Botswana.
    Leeme TB; Mine M; Lechiile K; Mulenga F; Mosepele M; Mphoyakgosi T; Muthoga C; Ngidi J; Nkomo B; Ramaabya D; Tau M; Tenforde MW; Hayes R; Jarvis JN
    HIV Med; 2021 Jan; 22(1):1-10. PubMed ID: 32876378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
    Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
    Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.
    ; Zwahlen M; Harris R; May M; Hogg R; Costagliola D; de Wolf F; Gill J; Fätkenheuer G; Lewden C; Saag M; Staszewski S; d'Arminio Monforte A; Casabona J; Lampe F; Justice A; von Wyl V; Egger M
    Int J Epidemiol; 2009 Dec; 38(6):1624-33. PubMed ID: 19820106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Finlayson R; Zaunders J; Smith D; Cooper DA
    AIDS; 2002 Feb; 16(3):359-67. PubMed ID: 11834947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD4/CD8 Ratio Recovery of Children and Adolescents Living With HIV With Virological Suppression: A Prospective Cohort Study.
    Han WM; Apornpong T; Handoko R; Jantarabenjakul W; Gatechompol S; Ubolyam S; Kerr SJ; Avihingsanon A; Ruxrungtham K; Phanuphak P; Puthanakit T
    J Pediatric Infect Dis Soc; 2021 Mar; 10(2):88-96. PubMed ID: 32188991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
    Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.
    Lawn SD; Myer L; Bekker LG; Wood R
    BMC Infect Dis; 2006 Mar; 6():59. PubMed ID: 16551345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.
    Parczewski M; Siwak E; Leszczyszyn-Pynka M; Cielniak I; Burkacka E; Pulik P; Witor A; Muller K; Zasik E; Grzeszczuk A; Jankowska M; Lemańska M; Olczak A; Grąbczewska E; Szymczak A; Gąsiorowski J; Szetela B; Bociąga-Jasik M; Skwara P; Witak-Jędra M; Jabłonowska E; Wójcik-Cichy K; Kamerys J; Janczarek M; Krankowska D; Mikuła T; Kozieł K; Bielec D; Stempkowska J; Kocbach A; Błudzin W; Horban A
    J Int AIDS Soc; 2017 Jul; 20(1):21847. PubMed ID: 28715160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort.
    Takuva S; Maskew M; Brennan AT; Long L; Sanne I; Fox MP
    J Int AIDS Soc; 2014; 17(1):18651. PubMed ID: 24594114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.